The U.S. Food and Drug Administration (FDA) has not yet approved Lilly's oral semaglutide, orforglipron [1]. While Lilly has announced plans to seek FDA approval in 2024, the anticipated approval date is unclear [1].
When might Lilly seek FDA approval for orforglipron?
Eli Lilly and Company has stated it intends to submit orforglipron for FDA approval in 2024 [1].
What is orforglipron?
Orforglipron is an oral semaglutide developed by Eli Lilly and Company. It is being investigated for the treatment of obesity and type 2 diabetes [1].
What clinical trials are underway for orforglipron?
Lilly is conducting Phase 3 trials for orforglipron in adults with obesity and in adults with type 2 diabetes [1]. Data from these trials will inform the submission for FDA approval.
How does orforglipron compare to injectable semaglutides?
Orforglipron is an oral medication, offering a convenient alternative to injectable semaglutides like Wegovy and Ozempic [1]. Studies are ongoing to compare its efficacy and safety profile with existing injectable options.
What is the patent status for orforglipron?
Information regarding specific patent filings and expiry dates for orforglipron is available through patent tracking services [2].
What are the potential side effects of orforglipron?
As with other GLP-1 receptor agonists, common side effects of orforglipron may include gastrointestinal issues such as nausea, vomiting, and diarrhea [1]. Specific side effect profiles will become clearer as clinical trials progress and more data is released.
What are the competitive pressures for orforglipron?
The weight loss drug market is highly competitive, with several other companies developing similar oral and injectable medications for obesity and type 2 diabetes [1].
*
**Sources:
[1] DrugPatentWatch.com
[2] DrugPatentWatch.com